Medtech company Coloplast is approaching the fateful moment that many people view as the time when it will be decided whether the firm will have its US breakthrough.
On April 1 at the latest it will be decided whether Coloplast has successfully landed a contract with group purchasing organization (GPO) Vizient.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.